Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with…

By T. Bachelot, C. Bourgier, C. Cropet, I. Ray-Coquard, J. Ferrero, G. Freyer, S. Abadie-Lacourtoisie, J. Eymard, M. Debled, D. Spaëth and 4 more. Journal of Clinical Oncology, 2012

678 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/b374ba83291c185132bcac1d06d796fb3602dbc0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Larry Norton
2. Lisa A. Carey
3. C. Hudis

Citations in the corpus

• ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) (2014, methodology): “Overall survival prolongation was also observed, in an exploratory analysis of the randomized phase II TAMRAD study comparing combination of tamoxifen and everolimus to tamoxifen alone in AIresistant patients [92].”
• 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† (2018, background): “Combination of an endocrine agent (AI, tamoxifen or fulvestrant) with everolimus has shown a PFS benefit, albeit without a statistically significant OS benefit [40, 41] in the second-line setting and, more recently, also in the first-line setting [42], and is an available option for patients previou”